These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 31329022)

  • 21. PBP2a mutations causing high-level Ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates.
    Long SW; Olsen RJ; Mehta SC; Palzkill T; Cernoch PL; Perez KK; Musick WL; Rosato AE; Musser JM
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6668-74. PubMed ID: 25155594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular epidemiology and antibiotic resistance of methicillin-resistant Staphylococcus aureus circulating in the Russian Federation.
    Gostev V; Kruglov A; Kalinogorskaya O; Dmitrenko O; Khokhlova O; Yamamoto T; Lobzin Y; Ryabchenko I; Sidorenko S
    Infect Genet Evol; 2017 Sep; 53():189-194. PubMed ID: 28600216
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Gaikwad V; Gohel T; Panickar S; Chincholkar V; Mangalkar S
    Indian J Pathol Microbiol; 2016; 59(4):496-498. PubMed ID: 27721280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced In Vitro Activity of Ceftaroline by Etest among Clonal Complex 239 Methicillin-Resistant Staphylococcus aureus Clinical Strains from Australia.
    Abbott IJ; Jenney AW; Jeremiah CJ; Mirčeta M; Kandiah JP; Holt DC; Tong SY; Spelman DW
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7837-41. PubMed ID: 26392488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model.
    Singh R; Almutairi M; Alm RA; Lahiri SD; San Martin M; Chen A; Ambler JE
    J Antimicrob Chemother; 2017 Oct; 72(10):2796-2803. PubMed ID: 29091195
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of novel anti-MRSA cephalosporins and comparator antimicrobial agents against staphylococci involved in prosthetic joint infections.
    Isnard C; Dhalluin A; Malandain D; Bruey Q; Auzou M; Michon J; Giard JC; Guérin F; Cattoir V
    J Glob Antimicrob Resist; 2018 Jun; 13():221-225. PubMed ID: 29421316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Missense mutations of PBP2a are associated with reduced susceptibility to ceftaroline and ceftobiprole in African MRSA.
    Schaumburg F; Peters G; Alabi A; Becker K; Idelevich EA
    J Antimicrob Chemother; 2016 Jan; 71(1):41-4. PubMed ID: 26443816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of ceftaroline and ceftobiprole against methicillin-resistant Staphylococcus aureus with decreased susceptibility to vancomycin isolated in paediatric patients.
    Carnesecchi G; Lobello R; Liggieri L; Palmero C; Pescetto L; Morelli P; Castagnola E; Bandettini R
    J Chemother; 2018; 30(6-8):338-341. PubMed ID: 30375268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of an osteomyelitis case caused by dalbavancin, ceftaroline, and vancomycin non-susceptible methicillin-resistant Staphylococcus aureus.
    Dahdouh E; Díaz-Pollán B; Falces-Romero I; Mingorance J; Gómez-Gil R
    Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):2029-2032. PubMed ID: 33686556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of EUCAST ceftaroline breakpoint change on the susceptibility of methicillin-resistant Staphylococcus aureus isolates collected from patients with complicated skin and soft-tissue infections.
    Urbán E; Stone GG
    Clin Microbiol Infect; 2019 Nov; 25(11):1429.e1-1429.e4. PubMed ID: 30980925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Carbapenems drive the collateral resistance to ceftaroline in cystic fibrosis patients with MRSA.
    Varela MC; Roch M; Taglialegna A; Long SW; Saavedra MO; Rose WE; Davis JJ; Hoffman LR; Hernandez RE; Rosato RR; Rosato AE
    Commun Biol; 2020 Oct; 3(1):599. PubMed ID: 33093601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-susceptibility to ceftaroline in healthcare-associated multiresistant MRSA in Eastern Australia.
    Mubarak N; Sandaradura I; Isaia L; O'Sullivan M; Zhou F; Marriott D; Iredell JR; Harkness J; Andresen D
    J Antimicrob Chemother; 2015 Aug; 70(8):2413-4. PubMed ID: 25977400
    [No Abstract]   [Full Text] [Related]  

  • 33. In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolates Collected in 2012 from Latin American Countries as Part of the AWARE Surveillance Program.
    Biedenbach DJ; Hoban DJ; Reiszner E; Lahiri SD; Alm RA; Sahm DF; Bouchillon SK; Ambler JE
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7873-7. PubMed ID: 26416860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methicillin-resistant Staphylococcus aureus in Stockholm, Sweden: Molecular epidemiology and antimicrobial susceptibilities to ceftaroline, linezolid, mupirocin and vancomycin in 2014.
    Fang H; Fröding I; Gian B; Hæggman S; Tollström UB; Ullberg M; Nord CE
    J Glob Antimicrob Resist; 2016 Jun; 5():31-5. PubMed ID: 27436463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [In vitro activity of ceftaroline to MRSA isolates: a multicenter study].
    Mengeloğlu FZ; Taş T; Koçoğlu E; Copur Çiçek A; Yanık K; Güneş H; Ciftci IH; Durmaz S; Bucak O; Güçkan R; Terzi HA; Yavuz MZ
    Mikrobiyol Bul; 2013 Oct; 47(4):677-83. PubMed ID: 24237436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates.
    Vidaillac C; Leonard SN; Rybak MJ
    Int J Antimicrob Agents; 2010 Jun; 35(6):527-30. PubMed ID: 20346632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro ceftaroline combinations against meticillin-resistant Staphylococcus aureus.
    García AB; Candel FJ; López L; Chiarella F; Viñuela-Prieto JM
    J Med Microbiol; 2016 Oct; 65(10):1119-1122. PubMed ID: 27553740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program.
    Sader HS; Flamm RK; Farrell DJ; Jones RN
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S181-6. PubMed ID: 22903950
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicentre study of meticillin-resistant Staphylococcus aureus in acute bacterial skin and skin-structure infections in China: susceptibility to ceftaroline and molecular epidemiology.
    Zhang H; Xiao M; Kong F; O'Sullivan MV; Mao LL; Zhao HR; Zhao Y; Wang H; Xu YC
    Int J Antimicrob Agents; 2015 Apr; 45(4):347-50. PubMed ID: 25649348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence and genotypic relatedness of methicillin resistant Staphylococcus aureus in a tertiary care hospital.
    Fomda BA; Thokar MA; Bashir G; Khan A; Kour A; Zahoor D; Ray P
    J Postgrad Med; 2014; 60(4):386-9. PubMed ID: 25370547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.